These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16984627)

  • 1. Tuberculosis chemotherapy: current drug delivery approaches.
    du Toit LC; Pillay V; Danckwerts MP
    Respir Res; 2006 Sep; 7(1):118. PubMed ID: 16984627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
    Singh J; Garg T; Rath G; Goyal AK
    Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
    Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
    Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.
    Smith JP
    Yale J Biol Med; 2011 Dec; 84(4):361-9. PubMed ID: 22180674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tuberculosis-current therapeutic principles].
    Greinert U; Zabel P
    Internist (Berl); 2003 Nov; 44(11):1394-405. PubMed ID: 14689075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs.
    Anjani QK; Permana AD; Cárcamo-Martínez Á; Domínguez-Robles J; Tekko IA; Larrañeta E; Vora LK; Ramadon D; Donnelly RF
    Eur J Pharm Biopharm; 2021 Jan; 158():294-312. PubMed ID: 33309844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
    Kaur M; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent patents and advances on anti - tuberculosis drug delivery and formulations.
    Vora C; Patadia R; Mittal K; Mashru R
    Recent Pat Drug Deliv Formul; 2013 Aug; 7(2):138-49. PubMed ID: 23244680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.
    Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of tuberculosis].
    Eier A; Grass S
    Wien Med Wochenschr; 1994; 144(8-9):186-8. PubMed ID: 7941607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured drug delivery for better management of tuberculosis.
    Kaur IP; Singh H
    J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
    Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
    Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.